anti-BPI antibody product blog
Tags: Antibody; BPI; Monoclonal Antibody; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; anti-BPI antibody;
The BPI bpi (Catalog #MBS604935) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The BACTERICIDAL PERMEABILITY INCREASING PROTEIN (BPI, CAP57) reacts with Human and may cross-react with other species as described in the data sheet.Suitable for use in immunoassays both as coating and as detector. Researchers should empirically determine the suitability of the BPI bpi for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The BPI bpi product has the following accession number(s) (GI #27806919) (NCBI Accession #NP_776320.1) (Uniprot Accession #P17453). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
The antimicrobial protein BPI is a 55kD protein found in the primary (azurophilic) granules of human neutrophils and has also been detected on surface of neutrophils, small intestinal and oral epithelial cells. BPI is a bactericidal compound that is present in polymorphonuclear cells (PMN) and in lower levels in the specific granules of eosinophils. BPI possesses high affinity toward the lipid A region of lipopolysaccharides (LPS) that comprise the outer leaflet of the gram-negative bacterial outer membrane. Binding of BPI to the lipid A moiety of LPS exerts multiple anti-infective activities against gram-negative bacteria: 1) cytotoxicity via sequential damage to bacterial outer and inner lipid membranes, 2) neutralization of gram-negative bacterial LPS, 3) opsonization of bacteria to enhance phagocytosis by neutrophils. Airway epithelial cells constitutively express the BPI gene and produce the BPI protein and, therefore, BPI may be a critical determinant in the development of LPS-triggered airways disease. Inflammation induced by LPS possibly contributes to the development of rapid airflow decline, a serious and often fatal complication of hematopoietic cell transplantation. Furthermore, a 21kD bioactive recombinant fragment of BPI, rBPI21, was shown to confer a survival advantage.
Immunogen: Human BPI. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing BPI are readily searchable from our website. Different antibodies against the same target such as BPI may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. Arthritis, Rheumatoid, Breast Neoplasms, Colitis, Immune System Diseases, Liver Diseases, Nausea, Neoplasms, Nervous System Diseases, Pain, Pulmonary Fibrosis are some of the diseases may be linked to BACTERICIDAL PERMEABILITY INCREASING PROTEIN (BPI, CAP57).